搜尋結果
Candida auris (C. auris) C. auris is an emerging fungus that can cause severe, often multidrug-resistant, infections. It spreads easily among patients in healthcare facilities.
2024年4月24日 · Candida auris (C. auris) is a type of yeast that can cause severe illness and spreads among patients in healthcare facilities. Symptoms of C. auris depend on the type of infection (i.e., bloodstream, wound, ears). C. auris is often resistant to antifungal C. auris.
2024年4月24日 · Environmental disinfection. C. auris can persist on surfaces in healthcare settings. C. auris has been cultured from multiple locations in patient rooms. The fungus has been found on both high-touch surfaces, such as bedside tables and bedrails, and surfaces farther away from the patient, such as windowsills.
2024年4月24日 · Candida auris (C. auris) is a fungus that can cause life-threatening, often multidrug-resistant, infections. C. auris affects ill or immunocompromised patients and is highly transmissible in healthcare settings.
2024年4月24日 · What to know. Patients who don't have symptoms can have Candida auris (C. auris) on their skin and spread it to other patients. Healthcare facilities screen patients for C. auris to stop it from spreading. Healthcare providers usually screen for C. auris by swabbing skin in the armpits or groins.
Some patients carry C. auris on their skin or other body sites without it causing symptoms (colonization). Both infected and colonized patients can spread C. auris. Healthcare providers use many strategies to help stop C. auris from spreading.
2024年4月24日 · Echinocandins are the initial recommended treatment for adults and children over 2 months. Amphotericin B deoxycholate at 1 mg/kg daily is the initial recommended treatment for infants under 2 months. Reports of echinocandin-resistant and pan-resistant cases are increasing.
2024年4月23日 · At a glance. All C. auris isolates should undergo antifungal susceptibility testing following Clinical and Laboratory Standards Institute (CLSI) guidelines. Breakpoints are defined based on those established for closely related Candida species and on expert opinion.
2024年4月24日 · In 2022 there were 2,377 clinical cases and 5,754 screening cases of Candida auri s (C. auris) reported to CDC. Clinical cases are patients who are tested to determine a cause of infection and receive positive results for C. auris. States have voluntarily reported cases to CDC since 2013.
2024年4月24日 · Screening patients for C. auris colonization is critical for preventing the spread of C. auris. Noninvasive skin swab collection and testing can identify patients who are colonized with C. auris. Use a composite swab of the patient's axilla (armpit) and groin (one swab is used to swab both areas).
